Catalyst Pharmaceuticals recently enrolled the first patient into a Phase 3 clinical trial designed to evaluate the efficacy and…
Articles by Margarida Azevedo, MSc
Dosing has been completed in the Phase 1 clinical trial of GTP-004, a new candidate for the treatment of symptoms associated…
Alexion Pharmaceuticals announced that it has received approval to market Soliris (eculizumab) in Japan as a treatment for certain adults with…
The Myasthenia Gravis Foundation of America (MGFA) started the MG Walk Campaign six years ago to raise funds, create awareness,…
The Assistance Fund recently launched a program to provide financial support to patients with myasthenia gravis (MG). The Assistance…
The Japanese Patent Office (JPO) has issued a new patent for the composition of eculizumab, marketed as Soliris by…
The first participant has been dosed in a Phase 1 clinical trial evaluating argenx‘s subcutaneous formulation of ARGX-113 in healthy…
The U.S. Food and Drug Administration has approved Soliris (eculizumab) as a treatment for adults with a particular type of …
The U.S. Food and Drug Administration has granted orphan drug status to ARGX-113, a potential treatment for myasthenia gravis, its…
Women with myasthenia gravis (MG) have a poorer quality of life than male patients. That’s the conclusion of a…